Arteriosclerosis Thrombosis and Vascular Biology · 2017 · 39 citations · 71 references
MedicineMolecular MedicinePathobiologyGene DeliveryGene TherapyLipid BiochemistryAtherosclerotic Cardiovascular Disease PreventionCardiovascular DiseaseCarotid Artery DiseaseLipid MetabolismLipid-lowering TherapyLipoprotein MetabolismAdenoviral TransgenesisAdenoviral VectorsAtherosclerosis Molecular MechanismsAtherosclerosis-associated MacrophagesAtherosclerotic Lipid AccumulationAtherosclerotic ProgressionCarotid Artery AtherosclerosisIntimal Hyperplasia
Objective— Gene therapy that expresses apo A-I (apolipoprotein A-I) from vascular wall cells has promise for preventing and reversing atherosclerosis. Previously, we reported that transduction of carotid artery endothelial cells with a helper-dependent adenoviral (HDAd) vector expressing apo A-I reduced early (4 weeks) fatty streak development in fat-fed rabbits. Here, we tested whether the same HDAd could provide long-term protection against development of more complex lesions. Approach and Results— Fat-fed rabbits (n=25) underwent bilateral carotid artery gene transfer, with their left and right common carotids randomized to receive either a control vector (HDAdNull) or an apo A-I–expressing vector (HDAdApoAI). Twenty-four additional weeks of high-fat diet yielded complex intimal lesions containing lipid-rich macrophages as well as smooth muscle cells, often in a lesion cap. Twenty-four weeks after gene transfer, high levels of apo A-I mRNA (median ≥250-fold above background) were present in all HDAdApoAI-treated arteries. Compared with paired control HDAdNull-treated arteries in the same rabbit, HDAdApoAI-treated arteries had 30% less median intimal lesion volume ( P =0.03), with concomitant reductions (23%–32%) in intimal lipid, macrophage, and smooth muscle cell content ( P ≤0.05 for all). HDAdApoAI-treated arteries also had decreased intimal inflammatory markers. VCAM-1 (vascular cell adhesion molecule-1)–stained area was reduced by 36% ( P =0.03), with trends toward lower expression of ICAM-1 (intercellular adhesion molecule-1), MCP-1 (monocyte chemoattractant protein 1), and TNF-α (tumor necrosis factor-α; 13%–39% less; P =0.06–0.1). Conclusions— In rabbits with severe hyperlipidemia, transduction of vascular endothelial cells with an apo A-I–expressing HDAd yields at least 24 weeks of local apo A-I expression that durably reduces atherosclerotic lesion growth and intimal inflammation.
71
Effects of Torcetrapib in Patients at High Risk for Coronary Events
Philip J. Barter, Mark J. Caulfield, Mats Eriksson et al. · New England Journal of Medicine · 2007 · 3.1K citations · Full text
Medicine, Cardiology, Pharmacology +14
Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
Gregory G. Schwartz, Anders Olsson, Markus Abt et al. · New England Journal of Medicine · 2012 · 2K citations · Full text
Medicine, Cardiology, Pharmacology +17
Steven E. Nissen, Taro Tsunoda, E. Murat Tuzcu et al. · JAMA · 2003 · 1.7K citations · Full text
Medicine, Cardiology, Pharmacology +14